Search alternatives:
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
281
The MCF-7 and/or MDA-MB-468 cells were treated with or without 10 μM Peptide 1 for 48h.
Published 2020Subjects: -
282
-
283
-
284
-
285
-
286
-
287
-
288
-
289
-
290
-
291
-
292
-
293
-
294
The SW480 cells were treated with the S100A1 (blue, Lanes 2, 3 and 4).
Published 2019“…<p>Decrease in fold was observed when treated with the complex of 100 nM S100A4-S100A1 (green) and value of <i>p</i> is considering as <i>p</i> ≤ 0.05.…”
-
295
-
296
-
297
-
298
-
299
Flowchart of patients.
Published 2024“…Using the number of competitors per distance method, our study showed that a “highly competitive” and “moderately competitive” markets decreased mortality by 31% [OR: 0.69 (0.59, 0.80); p<0.001] and by 12% respectively [OR: 0.88 (0.79, 0.99); p<0.03], compared to the “non-competitive” market. …”
-
300
Baseline characteristics of patients.
Published 2024“…Using the number of competitors per distance method, our study showed that a “highly competitive” and “moderately competitive” markets decreased mortality by 31% [OR: 0.69 (0.59, 0.80); p<0.001] and by 12% respectively [OR: 0.88 (0.79, 0.99); p<0.03], compared to the “non-competitive” market. …”